ILMN

134.87

1.16% -1.57

Handel nachbörslich: 135.00 0.13 +0.10%

Illumina Inc (ILMN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ILMN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$136.44

Offen:

$136.19

24-Stunden-Volumen:

1.70M

Relative Volume:

0.96

Marktkapitalisierung:

$20.61B

Einnahmen:

$4.28B

Nettoeinkommen (Verlust:

$1.26B

KGV:

17.08

EPS:

7.8957

Netto-Cashflow:

$943.00M

1W Leistung:

+4.57%

1M Leistung:

+10.56%

6M Leistung:

+53.02%

1J Leistung:

-7.90%

1-Tages-Spanne:

$134.13

$137.09

1-Wochen-Bereich:

$126.44

$137.09

52-Wochen-Spanne:

$68.70

$153.06

Illumina Inc Stock (ILMN) Company Profile

Firmenname

Illumina Inc

Sektor

Healthcare (1134)

Branche

Diagnostics & Research (54)

Telefon

(858) 202-4500

Adresse

5200 ILLUMINA WAY, SAN DIEGO, CA

Mitarbeiter

8,970

Twitter

@illumina

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ILMN's Discussions on Twitter

Vergleichen Sie ILMN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ILMN Illumina Inc	134.87	20.85B	4.28B	1.26B	943.00M	7.8957
TMO Thermo Fisher Scientific Inc	572.18	217.50B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	226.40	164.13B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	704.20	56.49B	4.17B	1.03B	940.22M	12.61
A Agilent Technologies Inc	139.70	40.44B	6.95B	1.30B	1.15B	4.5714
IQV Iqvia Holdings Inc	222.26	38.48B	15.90B	1.28B	2.21B	7.2842

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-12	Herabstufung	Daiwa Securities	Outperform → Neutral
2025-07-11	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2025-03-04	Bestätigt	Citigroup	Neutral
2025-02-28	Herabstufung	HSBC Securities	Buy → Hold
2025-02-10	Herabstufung	Barclays	Equal Weight → Underweight
2025-02-07	Herabstufung	TD Cowen	Buy → Hold
2024-12-11	Herabstufung	Citigroup	Buy → Neutral
2024-11-12	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-10-17	Hochstufung	HSBC Securities	Hold → Buy
2024-08-28	Hochstufung	Argus	Hold → Buy
2024-08-16	Hochstufung	Daiwa Securities	Neutral → Buy
2024-08-14	Hochstufung	Barclays	Underweight → Equal Weight
2024-08-14	Hochstufung	TD Cowen	Hold → Buy
2024-07-10	Hochstufung	Citigroup	Neutral → Buy
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-01-16	Herabstufung	HSBC Securities	Buy → Hold
2024-01-04	Herabstufung	TD Cowen	Outperform → Market Perform
2023-12-18	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2023-12-15	Hochstufung	Bernstein	Underperform → Mkt Perform
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-14	Eingeleitet	Stephens	Overweight
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Herabstufung	BofA Securities	Neutral → Underperform
2023-12-11	Hochstufung	Citigroup	Sell → Neutral
2023-11-10	Herabstufung	Canaccord Genuity	Buy → Hold
2023-09-28	Eingeleitet	Bernstein	Underperform
2023-07-05	Fortgesetzt	JP Morgan	Neutral
2023-01-25	Herabstufung	Argus	Buy → Hold
2023-01-05	Eingeleitet	Scotiabank	Sector Perform
2022-12-12	Herabstufung	Citigroup	Neutral → Sell
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-10-04	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-09-28	Hochstufung	Evercore ISI	In-line → Outperform
2022-08-25	Eingeleitet	Credit Suisse	Neutral
2022-07-13	Herabstufung	Barclays	Equal Weight → Underweight
2022-01-18	Hochstufung	Stifel	Hold → Buy
2022-01-11	Hochstufung	Barclays	Underweight → Equal Weight
2022-01-07	Hochstufung	BofA Securities	Underperform → Neutral
2022-01-06	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-01-06	Fortgesetzt	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-08-19	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-03-31	Herabstufung	Atlantic Equities	Overweight → Neutral
2021-03-31	Hochstufung	Canaccord Genuity	Hold → Buy
2021-03-03	Eingeleitet	Barclays	Underweight
2020-12-22	Hochstufung	Piper Sandler	Neutral → Overweight
2020-12-17	Hochstufung	BTIG Research	Neutral → Buy
2020-10-13	Herabstufung	Guggenheim	Buy → Neutral
2020-09-30	Eingeleitet	Atlantic Equities	Overweight
2020-09-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2020-09-22	Herabstufung	Stifel	Buy → Hold
2020-09-22	Herabstufung	UBS	Buy → Neutral
2020-09-21	Hochstufung	Guggenheim	Neutral → Buy
2020-09-21	Herabstufung	JP Morgan	Overweight → Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2020-08-07	Herabstufung	Evercore ISI	In-line → Underperform
2020-08-07	Herabstufung	Piper Sandler	Overweight → Neutral
2020-07-07	Herabstufung	Guggenheim	Buy → Neutral
2020-04-24	Herabstufung	Citigroup	Buy → Neutral
2020-04-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-01-08	Eingeleitet	Wells Fargo	Underweight
2020-01-07	Eingeleitet	Citigroup	Buy
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-11-15	Eingeleitet	Stifel	Buy
2019-10-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Illumina Inc Aktie (ILMN) Neueste Nachrichten

03:29 AM

Using genomic testing to deliver hope to families - Illumina

03:29 AM

10:58 AM

DNA Computing Market - GlobeNewswire Inc.

10:58 AM

Dec 11, 2025

Your lab’s new best friend for scalable proteomics: Illumina Protein Prep - Illumina

Dec 11, 2025

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually - marketscreener.com

Dec 11, 2025

Illumina invests in MyOme to advance AI-driven genomic health models By Investing.com - Investing.com India

Dec 11, 2025

Illumina (NASDAQ: ILMN) invests in MyOme to launch AI-driven WGS trial in 2026 - Stock Titan

Dec 11, 2025

Dec 10, 2025

Stifel reiterates Buy rating on Illumina stock, cites multiple growth levers - Investing.com Australia

Dec 10, 2025

Dec 09, 2025

Leadership Perspectives: Illumina leads the industry in genomic AI - Illumina

Dec 09, 2025

Does Surging Genomics Consumables Demand Reshape The Bull Case For Illumina’s Recurring Revenue Engine (ILMN)? - Yahoo Finance

Dec 09, 2025

Zacks.com featured highlights include Illumina, Commercial Metals and Newmont - Yahoo Finance

Dec 09, 2025

Dec 08, 2025

Precision oncology at your community’s doorstep - Illumina

Dec 08, 2025

Dec 06, 2025

Illumina Inc ILU Stock Analysis and ForecastAI-Driven Market Analysis & Free Lightning Fast Capital Gains - earlytimes.in

Dec 06, 2025

Dec 05, 2025

Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound - Yahoo Finance

Dec 05, 2025

Illumina (NASDAQ:ILMN) Upgraded at Zacks Research - MarketBeat

Dec 05, 2025

Illumina at the 2025 China International Import Expo (CIIE) - Illumina

Dec 05, 2025

Will Illumina Inc. (ILU) stock draw ESG focused funds2025 Top Decliners & Smart Swing Trading Techniques - Newser

Dec 05, 2025

How Illumina Inc. (ILU) stock reacts to fiscal policiesPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - Newser

Dec 05, 2025

Dec 04, 2025

AI in Biotech Market Is Booming Worldwide | NVIDIA, Illumina - openPR.com

Dec 04, 2025

Epigenetics Market size to reach $8.63 Billion by 2035 | Key - openPR.com

Dec 04, 2025

American Century Companies Inc. Sells 32,763 Shares of Illumina, Inc. $ILMN - MarketBeat

Dec 04, 2025

Dec 03, 2025

Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance

Dec 03, 2025

Schroder Investment Management Group Raises Stock Holdings in Illumina, Inc. $ILMN - MarketBeat

Dec 03, 2025

Will Illumina Inc. (ILU) stock keep high P E multiplesTrade Signal Summary & Safe Capital Allocation Plans - Newser

Dec 03, 2025

Can Illumina Inc. (ILU) stock sustain revenue momentumJuly 2025 Setups & Entry Point Confirmation Signals - Newser

Dec 03, 2025

Korea Investment CORP Reduces Position in Illumina, Inc. $ILMN - MarketBeat

Dec 03, 2025

Why Illumina Inc. (ILU) stock fits value portfoliosOil Prices & Fast Exit/Entry Strategy Plans - Newser

Dec 03, 2025

Dec 02, 2025

Genetic testing transformed her cancer care—and her family tree - Illumina

Dec 02, 2025